Scholarlink

<p>Triple-negative breast cancer (TNBC) is a heterogeneous disease with variable response to neoadjuvant systemic therapy (NAST). Patients with pathologic complete response (pCR) following NAST have improved survival. Our goal was to establish readily accessible imaging biomarker to identify which TNBC patients will have pCR. Building on prior favorable results in the literature, we hypothesized that manually measured tumor volume changes at DCE-MRI may predict pCR early during NAST. This prospective study included 287 stage I-III TNBC patients who underwent DCE-MRI at baseline, after two and four cycles of NAST, with pCR accessed at surgery (NCT02276443). Tumor volume and percentage tumor volume reduction were calculated, and their correlation with pCR was evaluated. Our study showed that manually extracted tumor volume changes from DCE-MRI early during NAST were able to predict pCR with high accuracy and can serve as a clinically relevant imaging biomarker for prediction of NAST response in TNBC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月20日

查看全文
  • Mary S. Guirguis,
  • Beatriz E. Adrada,
  • Clinton Yam,
  • Debu Tripathy,
  • Rosalind Candelaria,
  • Wei Yang,
  • Miral Patel,
  • Tanya Moseley,
  • Frances Perez,
  • Gary J. Whitman,
  • Jessica W. T. Leung,
  • Huong Le-Petross,
  • Deanna L. Lane,
  • Lei Huo,
  • Jennifer K. Litton,
  • Vicente Valero,
  • Kelly K. Hunt,
  • Banu Arun,
  • Rania Mohamed,
  • Jia Sun,
  • Anil Korkut,
  • Zhan Xu,
  • Sanaz Pashapoor,
  • Jason White,
  • Jong Bum Son,
  • Alastair Thompson,
  • Peng Wei,
  • Jingfei Ma,
  • Stacy Moulder,
  • Gaiane M. Rauch

摘要

Triple-negative breast cancer (TNBC) is a heterogeneous disease with variable response to neoadjuvant systemic therapy (NAST). Patients with pathologic complete response (pCR) following NAST have improved survival. Our goal was to establish readily accessible imaging biomarker to identify which TNBC patients will have pCR. Building on prior favorable results in the literature, we hypothesized that manually measured tumor volume changes at DCE-MRI may predict pCR early during NAST. This prospective study included 287 stage I-III TNBC patients who underwent DCE-MRI at baseline, after two and four cycles of NAST, with pCR accessed at surgery (NCT02276443). Tumor volume and percentage tumor volume reduction were calculated, and their correlation with pCR was evaluated. Our study showed that manually extracted tumor volume changes from DCE-MRI early during NAST were able to predict pCR with high accuracy and can serve as a clinically relevant imaging biomarker for prediction of NAST response in TNBC patients.